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Abstract
Background: Protection of pigs by vaccination against Actinobacillus pleuropneumoniae, the causative agent of porcine
pleuropneumonia, is hampered by the presence of 15 different serotypes. A DIVA subunit vaccine comprised of
detergent-released proteins from A. pleuropneumoniae serotypes 1, 2 and 5 has been developed and shown to protect
pigs from clinical symptoms upon homologous and heterologous challenge. This vaccine has not been characterized
in-depth so far. Thus we performed i) mass spectrometry in order to identify the exact protein content of the vaccine
and ii) cross-serotype 2-D immunoblotting in order to discover cross-reactive antigens. By these approaches we
expected to gain results enabling us to argue about the reasons for the efficacy of the analyzed vaccine.
Results: We identified 75 different proteins in the vaccine. Using the PSORTb algorithm these proteins were
classified according to their cellular localization. Highly enriched proteins are outer membrane-associated
lipoproteins like OmlA and TbpB, integral outer membrane proteins like FrpB, TbpA, OmpA1, OmpA2, HgbA and
OmpP2, and secreted Apx toxins. The subunit vaccine also contained large amounts of the ApxIVA toxin so far
thought to be expressed only during infection. Applying two-dimensional difference gel electrophoresis (2-D DIGE)
we showed different isoforms and variations in expression levels of several proteins among the strains used for
vaccine production. For detection of cross-reactive antigens we used detergent released proteins of serotype 7.
Sera of pigs vaccinated with the detergent-released proteins of serotypes 1, 2, and 5 detected seven different
proteins of serotype 7, and convalescent sera of pigs surviving experimental infection with serotype 7 reacted with
13 different proteins of the detergent-released proteins of A. pleuropneumoniae serotypes 1, 2, and 5.
Conclusions: A detergent extraction-based subunit vaccine of A. pleuropneumoniae was characterized by mass
spectrometry. It contained a large variety of immunogenic and virulence associated proteins, among them the
ApxIVA toxin. The identification of differences in expression as well as isoform variation between the serotypes
implied the importance of combining proteins of different serotypes for vaccine generation. This finding was
supported by immunoblotting showing the induction of cross-reactive antibodies against several surface associated
proteins in immunized animals.
Background
Actinobacillus pleuropneumoniae is a gram-negative
rod-shaped bacterial pathogen causing porcine pleurop-
neumonia, a highly contagious disease for pigs which is
often fatal and leads to severe economic losses in the
swine industry worldwide [1]. Transmission occurs by
aerosols or close contact with infected pigs [2] and it
can cause mild to severe clinical signs depending on ser-
otype, infectious dose, and immune status of the animal.
Acute infection is characterized by hemorrhagic, fibri-
nous pneumonia often leading to rapid death of affected
animals. Pigs surviving the infection can become chroni-
cally infected asymptomatic carriers of A. pleuropneu-
moniae. Carrier animals, in which the pathogen is able
to persist for months in sequestered lung tissue and in
tonsils, can transmit the disease to healthy animals and
are the major source for new outbreaks [3,4].
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biotypes based on their dependency on exogenous
NADH. Biotype 1 strains are NADH auxotrophic
whereas strains belonging to biotype 2 are capable of
synthesizing NADH autonomously. Fifteen different ser-
otypes have been described on the basis of capsular
antigens [5]. All serotypes are obligate pathogens, but
differ in virulence [6] and regional distribution. Sero-
types 1, 5 and 7 are predominant in North America, ser-
otype 2 is most common to Europe [7] and serotypes 1,
3, 4, 5 and 7 are typically isolated in China [8]. This
diversity has hampered vaccination against porcine
pleuropneumonia and there is no fully efficacious vac-
cine offering complete protection against all serotypes to
date. Vaccination against bacterial pathogens has gained
increasing relevance due to growing problems with anti-
biotic resistance and rising consumer demands concern-
ing food safety [9].
Commercial vaccines against A. pleuropneumoniae
infection mostly consist of whole cell bacterins [9].
Although reducing mortality, they commonly do not
prevent infection or development of the carrier state.
Additionally, protection is limited to the serotype(s)
used in the vaccine preparation, and differentiation
between infected and vaccinated animals is not possible
[4,9-11]. The reproducible production of bacterin vac-
cines essentially depends on standard production rou-
tines for procedures such as culture and inactivation of
the bacteria. However, the molecular composition of
bacterin vaccines is generally not known. Thereby qual-
ity control and comparison between different production
lots is limited.
To overcome these limitations subunit vaccines have
been developed for different bacteria containing a subset
of bacterial antigens [9]. Generally, these antigens are
immunogenic, expressed in vivo,a n d-t oc o n f e rc r o s s -
serotype protection - are conserved among different
strains. To discover new potential vaccine components
for A. pleuropneumoniae the outer membrane proteome
has been resolved [12] and immunogenic outer mem-
brane as well as secreted proteins have been identified
[13,14]. Also, gene expression in vivo has been analyzed,
and protein expression studies under conditions
mimicking the in vivo situation (e.g. iron restriction,
addition of BALF, anaerobic conditions) have been
reported [15-19].
An A. pleuropneumoniae subunit vaccine was devel-
oped from cultures grown under iron restriction by
mild detergent extraction of proteins without lysing
the bacteria [20]. This subunit vaccine was postulated
to be enriched in outer membrane lipoproteins as
suggested by the presence of transferrin binding lipo-
protein B (TbpB) and the outer membrane lipoprotein
A (OmlA) whereas periplasmic, cytoplasmic and
membrane proteins were absent [20]. Vaccination of
pigs with this vaccine derived from A. pleuropneumo-
niae apxIIA-mutants of serotypes 1, 2 and 5 showed
good protective efficacy upon homologous challenge
with serotype 2 and cross-protection against serotype 9
and facilitated the differentiation between infected and
vaccinated animals [21].
In this study we set out to fully characterize the subu-
nit vaccine by addressing the following questions: i)
What is the exact protein composition of the vaccine?
ii) Which proteins might be responsible for cross-sero-
type protectivity? Thus we analyzed the serotype-specific
vaccine components by ultra performance liquid chro-
matography-coupled tandem mass spectrometry (UPLC
MS/MS) and two-dimensional difference gel electro-
phoresis (2-D DIGE). We additionally tested the efficacy
of the subunit vaccine to induce antibodies detecting
homologous proteins of a different serotype and used A.
pleuropneumoniae serotype 7 for that purpose.
Results
Proteomic analysis of vaccine components
For characterization of the subunit vaccine we used a
strategy designated “whole vaccine-proteome approach”.
A single preparation of detergent released proteins (des-
ignation: “detergent-wash”)o fe a c ho ft h eA. pleurop-
neumoniae serotypes contained in the vaccine was
separated by SDS-PAGE (Additional file 1, Figure S1)
and analyzed by UPLC-coupled Q-TOF MS/MS.
In each analysis several hundred masses were automa-
tically subjected to fragmentation and determination of
false discovery rate (FDR) revealed values of above 5%
erroneously identified proteins when including “single-
peptide-identifications”. Only one protein was identified
from the decoy database searches by two peptide
matches. Thus, for the whole vaccine-proteome
approach we defined a threshold of at least two peptide
matches for sufficient protein identification. This
approach led to the identification of 47, 43, and 36 dif-
ferent proteins for the “detergent-wash” of A. pleurop-
neumoniae serotypes 1, 2 and 5, respectively. In total 64
different proteins were identified by at least two peptide
matches in the “detergent wash” from serotypes 1, 2,
and 5. Thirty-two of these proteins were present in the
preparations of each of the three strains (Additional file
2 ,T a b l eS 1 ) .F o u r t e e np r o t e i n sw e r ei d e n t i f i e db ya t
least 10 peptide matches in one of the serotypes (Table
1). These proteins were designated as “abundant protein
fraction” of the subunit vaccine.
Analysis of the cellular location using PSORTb version
3.0 http://www.psort.org/psortb/ revealed that eight of
14 proteins of the “abundant protein fraction” are outer
membrane proteins (FrpB, OmlA TbpB, TbpA, OmpA1,
OmpA2, HgbA and OmpP2). High numbers of peptide
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toxins IA, IIIA and IVA contained in the “detergent-
wash”. Additionally, two cytosolic proteins (TufB2 and
FusA) as well as a periplasmic protein (YfeA) were iden-
tified with more than 10 peptide matches (Table 1).
Comparison of serotype-specific vaccine components by
2-D DIGE
The vaccine components from A. pleuropneumoniae ser-
otypes 1, 2 and 5 were labelled with different fluorescent
dyes and separated by 2-dimensional gel electrophoresis
(2-DE) on the same gel (Figure 1A-C). As we only used
a single protein preparation and did not intend to per-
form an exact quantification but rather describe the
content of the subunit vaccine, only spots showing
obvious differences in spot intensity between the three
strains were used for spot selection. Quantitative differ-
ences between spots of the three different serotypes
used for vaccine generation are provided additionally
(Additional file 3, Table S2). Spots were picked from
respective preparative gels (Additional file 4, Figure S2),
trypsinized and analyzed by either UPLC-coupled ESI
Q-TOF MS/MS or MALDI-TOF MS (Additional file 3,
Table S2).
Table 1 List of the “abundant protein fraction” identified in the A. pleuropneumoniae “detergent wash” preparations
upon 1-D PAGE.
Protein description
a)
Protein
a)
Accession
#
a)
Peptide matches
b) PSORTb
localization
c)
PSORTb
score
c)
Characteristics
d)
Subunit vaccine
Ser 1 Ser 2 Ser 5 Ser 7
RTX toxin protein ApxIA Q548V0 24 (1)
e) 29 (1)
e) Extracellular 10 Immunogenic [40]
RTX toxin protein ApxIIIA P55130 (2)
e) 26 (1)
e) (1)
e) Extracellular 10 Immunogenic [13]
Iron regulated outer
membrane protein B
FrpB B3H0B8 18 15 21 17 OuterMembrane 10 Immunogenic [13]
Outer membrane
lipoprotein A
OmlA B3GYZ9 19 14 10 19 OuterMembrane 9.92 Immunogenic [42]
Transferrin binding
protein
TbpB B3GYQ1 14 14 19 17 OuterMembrane 9.49 Immunogenic [41]
RTX toxin protein ApxIVA B3H1M8 10 16 15 0 Extracellular 10 Immunogenic [30]; expressed in
vivo [34]; upregulated in vivo [36]
Transferrin binding
protein 1 Tbp1
TbpA B3GYQ0 74 1 6 11 OuterMembrane 10 Immunogenic [41]; expressed in
vivo [34]
Elongation factor Tu TufB1,
TufB2
B3GYJ3 16 14 16 15 Cytoplasmic 9.97 Immunogenic [13]; expressed in
vivo [34,35]
Outer membrane
protein P5
OmpA1 B3H2D9 99 1 4 10 OuterMembrane 10 Immunogenic [13]; expressed in
vivo [34]; in vivo survival [37];
antigenic and in vivo expressed [14]
Elongation factor G FusA B3H2G7 41 2 1 26 Cytoplasmic 9.97
Outer membrane
protein P5 OMP P5
OmpA2 B3GZA8 10 11 10 7 OuterMembrane 10 Immunogenic [13]; expressed in
vivo [34]; in vivo survival [37];
antigenic and in vivo expressed [14]
Hemoglobin binding
protein A
HgbA B3H1S8 10 6 0 9 OuterMembrane 10 Expressed in vivo [34]
Outer membrane
protein P2
OmpP2 B3H172 10 9 10 8 OuterMembrane 10 in vivo survival [38]
Iron Chelated ABC
transporter
periplasmic binding
protein
YfeA B3H0B4 69 1 0 10 Periplasmic 10 Immunogenic [13]
Protein identifications in the individual “detergent washes” of the A. pleuropneumoniae serotypes 1, 2 and 5 used for generation of the subunit vaccine ("whole
vaccine-proteome approach”, highlighted in bold) and serotype 7.
a) In order to have a consistent nomenclature for proteins identified from A. pleuropneumoniae serotypes 1, 2, 5 or 7 in the columns “protein description”,
“protein” and “accession number”, the annotation of the respective homologue of A. pleuropneumoniae serotype 7 was adopted from the uniprot knowledgebase
http://www.uniprot.org/. For the Apx toxins ApxIA and ApxIIIA, which are not present in A. pleuropneumoniae serotype 7, the common nomenclature was used.
b) Peptide matches in the serotype specific vaccine components identified by UPLC-coupled Q-TOF MS/MS
c) Subcellular prediction using the PSORTb v.3.0 tool at http://www.psort.org/psortb/[53]. A probability based score from 0 (low probability) to 10 (high
probability) is given.
d) The identified proteins were searched in the literature for homologues identified in A. pleuropneumoniae as immunogenic, virulence-associated or relevant in
vivo.
e) These peptides from Apx toxins that are not present in the respective preparations because they are not encoded by the respective serotype were merely
identified because they are identical or highly homologous to peptides from other Apx toxins that are present in the respective preparations.
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Figure 1 2-D DIGE of “detergent-wash” proteins from A. pleuropneumoniae serotypes 1, 2 and 5 (subunit vaccine) and serotype 7. For
analysis of the subunit vaccine serotype 1, 2, and 5 were labelled with Cy2 (shown in blue), Cy3 (shown in green) and Cy5 (shown in red),
respectively, and subsequently pooled. For visualization of differences between the serotypes used for vaccine generation, we compared couples
of serotypes 1 and 2 (A), serotypes 1 and 5 (B), and serotypes 2 and 5 (C). For comparison of the subunit vaccine to serotype 7, the subunit
vaccine was labelled with Cy3 (shown in green) and the “detergent wash” of serotype 7 was labelled with Cy5 (shown in red, D). Spots with
intensities considerably above that in one or the other serotype were analyzed by mass spectrometry from preparative gels of the respective
serotype (Additional file 4, Figure S2). The annotation of the identified protein is given in the same colour as the labelling of the respective
serotype. The numbers on each spot, that has been identified, are consecutive and allow the finding of the respective spot on preparative gels
(Additional file 4, Figure S2).
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resulted in almost no false positive discoveries as gener-
ally fewer spectra were subjected to database searches
than in the “whole vaccine-proteome approach”.T h u s ,
we also included “single-peptide-identifications” as
results but confirmed these further according to the
procedure for MALDI-TOF MS results not having a sig-
nificant score (as described in Methods).
For A. pleuropneumoniae serotypes 1, 2 and 5 mass
spectrometry was successful for 30, 26 and 39 spots,
respectively, and led to the identification of 16, 16 and
22 different proteins. In total 36 different proteins were
identified from gels of the three A. pleuropneumoniae
serotypes (Additional file 3, Table S2). Eleven of these
36 proteins were not identified by the “whole vaccine-
proteome approach” using a threshold of at least two
peptide identifications (Additional file 2, Table S1). A
combination of the “whole vaccine-proteome approach”
and the gel-based approach resulted in the identification
of a total of 75 different proteins present in the subunit
vaccine.
Series of spots that appear as horizontal strings were
generally identified as belonging to the same protein.
Especially the Apx toxins were represented by several
spots in each serotype. Adjacent spots from different
serotypes having only a slight shift in pI or mass were
also often identified as homologous proteins. For exam-
ple UshA of A. pleuropneumoniae serotype 5 is repre-
sented by two additional spots adjacent to those of A.
pleuropneumoniae serotypes 1 and 2. Also, the outer
membrane proteins OmpA1, OmpP1 and OmpP2 differ
in mass and pI among the different A. pleuropneumo-
niae serotypes (Figure 1A-C).
Serotype-specific protein expression
We analyzed the combined data from the “whole vac-
cine-proteome approach” (Table 1, Additional file 2,
Table S1) and 2-D DIGE (Additional file 3, Table S2) to
compare protein expression between the different A.
pleuropneumoniae serotypes. As controls the Apx pro-
tein profiles were analyzed. As expected, the ApxIA
toxin was identified from gels of A. pleuropneumoniae
s e r o t y p e1a n d5a sw e l la sb yt h e“whole vaccine-pro-
teome approach” but not from A. pleuropneumoniae
serotype 2 by both methods. The ApxIIIA toxin was
only present on A. pleuropneumoniae serotype 2 gels
a n di d e n t i f i e db yt h e“whole vaccine-proteome
approach” from this serotype only. ApxIVA was identi-
fied from 2-DE gels of A. pleuropneumoniae serotypes 1,
2a n d5a sw e l la sb yt h e“whole vaccine-proteome
approach” from these serotypes.
The hemoglobin binding protein HgbA was found on
2-DE gels from A. pleuropneumoniae serotypes 1 and 2
as well as by the “whole vaccine-proteome approach”
with 10 and six peptides, respectively, but HgbA was
not found for A. pleuropneumoniae serotype 5 by either
approach. UshA was represented by more prominent
spots on gels of A. pleuropneumoniae serotypes 1 and 2
compared to serotype 5. This protein was identified by
the “whole vaccine-proteome approach” from A. pleur-
opneumoniae serotypes 1 and 2 with five and four pep-
tides, respectively, but only by one peptide from
serotype 5. On the other hand, the D-galactose-binding
protein MglB2 was represented by a prominent spot on
the A. pleuropneumoniae serotype 5 gel and identified
by four peptides from serotype 5 exclusively. Expression
of the transferrin binding protein 1 (TbpA) was identi-
fied by 2-D DIGE as increased in A. pleuropneumoniae
serotypes 1 and 5 compared to serotype 2; this finding
was supported by the result of the “whole vaccine-pro-
teome approach”.
The “whole vaccine-proteome approach” revealed the
identification of the autotransporter adhesins AtaB and
AtaA by five peptides and two peptides, respectively,
only from serotype 2. Additionally, homologues to the
uncharacterized protein APP7_1946 and the hybrid per-
oxyredoxin protein APP7_1490 were represented by
more prominent spots on A. pleuropneumoniae serotype
2 gels. UPLC-coupled tandem mass spectrometry sup-
ported this observation as five peptides were identified
for APP7_1946 and APP7_1490 in serotype 2 but only
one peptide was identified for each protein from A.
pleuropneumoniae serotype 1 and none from serotype 5
preparations.
Identification of cross-reactive antigens by
immunoproteomics
In order to test the efficacy of the subunit vaccine to
induce cross-serotype reactive antibodies, we used
“detergent-wash” proteins from serotype 7 strain AP76.
For that purpose the “detergent-wash” of serotype 7 was
characterized in advance and was analyzed as described
for the vaccine containing serotypes 1, 2, and 5 by 1-D
electrophoresis (Additional file 1, Figure S1) followed by
UPLC-coupled ESI Q-TOF MS/MS, which led to the
identification of 33 different proteins (Table 1, Addi-
tional file 2, Table S1). Most of the proteins that had
been identified for serotype 7 were also present in the
subunit vaccine. For the majority of the identified pro-
teins the number of peptide matches was in the same
range as found for the vaccine strains. As we used a ser-
otype 7 wild type strain we could identify the ApxIIA
protein which was absent from the vaccine strains that
were apxIIA deletion mutants. Additionally the unchar-
acterized protein APP7_1217 was only found in serotype
7. In contrast to serotypes 1, 2, and 5 no ApxIVA pro-
tein was identified in the serotype 7 “detergent-wash”
(Table 1, Additional file 2, Table S1).
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wash” of A. pleuropneumoniae serotype 7 and the subu-
nit vaccine (Figure 1D). ApxIIA of serotype 7 was iden-
tified on the gel as a series of horizontal spots. Some
serotype 7 proteins had similar masses but different iso-
e l e c t r i cp o i n t sa sc o m p a r e dt op r o t e i n so ft h es u b u n i t
vaccine. PckA and UshA and HgbA had more alkaline
isoelectric points whereas YfeA was shifted to the acidic
side (Figure 1D).
For the identification of cross-reactive antibodies
induced by vaccination with the subunit vaccine we
performed immunoblotting of serotype 7 “detergent-
wash” proteins and used sera of pigs immunized with
the subunit vaccine (Figure 2A). These sera detected
seven different proteins from serotype 7 (ApxIIA, D15,
UshA, FrpB, TufB, OmpA1, and OmpA2).
To compare the immunological efficacy of vaccination
with the subunit vaccine to a natural infection we subse-
quently probed subunit vaccine proteins with convales-
cent sera of pigs experimentally infected with A.
pleuropneumoniae serotype 7 (Figure 2B) and detected
13 different proteins. The proteins D15, UshA, TufB,
protein of Ser 7; sera of pigs immunized with protein pool of Ser 1, Ser 2 and Ser 5
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Figure 2 Immunoblot analysis for the identification of cross-reactive proteins. “Detergent-wash” proteins were separated by 2-D and
subsequently Western blotted. “Detergent-wash” proteins from serotype 7 were probed using immune sera of pigs immunized with the subunit
vaccine (A) and the subunit vaccine was probed with convalescent sera from pigs upon experimental infection with serotype 7 (B).
Immunogenic spots were assigned to spots on preparative Coomassie stained gels (Additional file 4, Figure S2) and identified by mass
spectrometry. The numbers on each spot that has been identified allow the finding of the respective spot on preparative gels (Additional file 4,
Figure S2).
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sera further detected RpsA, FusA, ApxIA, ApxIIIA, Tal,
FkpA, ZnuA, YfeA and APP7_0756. As controls we
used different protein preparations of serotype 7 and did
immunoblotting with sera of pigs that were neither
infected with A. pleuropneumoniae nor immunized with
the subunit vaccine. These sera detected only OmpA,
OmpP2 and ApxIIA very weakly and considerably less
than upon infection or vaccination (data not shown).
We tested the conservation of the detected cross-reac-
tive proteins and compared serotype 7 strain AP76 to
serotype 1 strain 4047, serotype 2 strain 4226, and sero-
type 5b strain L20 for which genomic sequences are
available on NCBI by doing “BLAST align two
sequences” analyses. The identities on the amino acid
level were above 98% for all proteins except for the Apx
toxins which are not present in all serotypes and the
elongation factors RpsA and TufB which were truncated
or discontinuous in serotype 2.
Discussion
Treatment of A. pleuropneumoniae grown under iron
restriction with the mild detergent sodium deoxycholate
has been introduced as a suitable method for enrich-
ment of antigenic outer membrane-associated lipopro-
teins [20]. A preparation of proteins obtained by this
method derived from apxIIA deletion mutants of A.
pleuropneumoniae s e r o t y p e s1 ,2a n d5w a su s e da sa
DIVA subunit vaccine and protected pigs from clinical
signs upon homologous challenge with A. pleuropneu-
moniae serotype 2 and heterologous challenge with ser-
otype 9 [21]. However, the protein composition of this
subunit vaccine has not been determined so far and,
therefore, was addressed in this study using state-of-the-
art proteomic technologies.
A combination of different bioinformatic tools pre-
dicted 93 outer membrane proteins for A. pleuropneu-
moniae serotype 5b [12] and searching the serotype 5b
genome with the SLEP pipeline (http://www.caspur.it/
slep[22]), which optimally combines several prediction
tools, revealed even more outer membrane or secreted
proteins. Our analyses led to the identification of 75 dif-
ferent proteins of which 15 proteins are membrane pro-
teins and four are secreted proteins as predicted by the
PSORTb algorithm. Thus several predicted outer mem-
brane and secreted proteins were not identified by our
approach, which is likely due to their low concentration
or even absence in the vaccine preparation.
As a semi-quantitative measure we postulate a corre-
lation between identified peptide matches and protein
abundance. Of 64 proteins identified in total by UPLC
Q-TOF MS/MS, 14 were identified by 10 or more pep-
tide matches. These proteins were therefore designated
as the “abundant protein fraction”. Among these three
Apx toxins and eight outer membrane proteins were
found. This approach showed that the detergent
extraction not only enriched outer membrane-asso-
ciated lipoproteins like OmlA and TbpB [20], but also
integral outer membrane proteins like FrpB, TbpA,
OmpA1, OmpA2, HgbA and OmpP2. Only three of
t h eh i g h l ye n r i c h e dp r o t e ins are cytosolic (TufB
and FusA) or periplasmic (YfeA). Their percentage
is higher in the fraction of low abundant vaccine
proteins and might be caused by lysed cells as well as
by the release of membrane vesicles containing these
proteins [23].
A combined interpretation of the “whole vaccine-pro-
teome approach” and the 2-D DIGE analysis revealed
different amounts for several proteins in the “detergent-
wash” preparations of the three serotypes, indicating ser-
otype dependent differences in gene expression. Addi-
tionally, the 2-DIGE analysis showed the presence of
various isoforms for several proteins among and
between the different strains that vary slightly in mass
or isoelectric point. For proteins represented by different
isoforms, a high ratio-value often means that only the
respective isoform is abundant in one or the other
strain. However, this does not necessarily refer to the
total amount of the respective protein, which holds true
e.g. for the outer membrane protein OmpP2. This pro-
tein was identified by comparable peptide numbers
between the different serotypes on the one hand, but
also appeared in several isoforms with high ratio-values
in each strain on the other hand.
With an exception of ApxIIA, all secreted Apx toxins
(including ApxIVA) produced by the A. pleuropneumo-
niae strains used for vaccine generation were detected,
and they represent the most abundant protein fraction
of the analyzed subunit vaccine. ApxIIA was not identi-
fied as apxIIA gene deletion mutants of A. pleuropneu-
moniae serotypes 1, 2 and 5 had been used for vaccine
generation in order to generate a DIVA vaccine [21].
T h eA p xt o x i n sa r ei m p o r t a n tf o rv i r u l e n c e[ 2 4 , 2 5 ]
and subunit vaccines based on Apx toxins have been
developed, eg. Porcillis APP™ (Intervet, [26]). Therefore,
the high content of ApxIA, ApxIIIA and ApxIVA in the
analyzed subunit vaccine is presumably one important
factor accounting for the protective efficacy of the
“detergent-wash” vaccine.
ApxIA and ApxIIIA were identified on 2-DE gels as
series of up to 10 spots with different isoelectric points,
which is likely caused by charged posttranslational mod-
ifications (PTMs). Different isoforms of other proteins
were also present within and between strains. As it can-
not be excluded that these isoforms vary with respect to
their protective efficacy for vaccination purposes, A.
pleuropneumoniae-derived proteins might be superior in
comparison to recombinant proteins.
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is immunogenic and encoded by most A. pleuropneumo-
niae isolates [27-29]. It was shown for serotype 7 strain
AP76 that the apxIVA gene is interrupted by an inser-
tion element preventing in vivo expression of apxIVA
[29]. This is in accordance with our data showing no
A p x I V Ap r o t e i ni nt h e“detergent-wash” of AP76.
Expression of the apxIVA gene has been considered for
long as strictly induced in vivo [30] and was shown
recently to be upregulated by bronchoalveolar fluid
[19,31]. We show for the first time the translation of the
apxIVA gene and identified abundant amounts of the
respective protein in the “detergent-washes” of A. pleur-
opneumoniae serotypes 1, 2, and 5. This presence of
ApxIVA in the analyzed subunit vaccine is likely to con-
tribute to immune protection of vaccinated pigs [32].
As we have grown A. pleuropneumoniae for vaccine
generation under iron restrictive conditions, one might
argue that these conditions induce apxIVA expression.
However, in contrast to many other proteins that were
highly enriched in the subunit vaccine, iron restrictive
induction of apxIVA has not been observed while ana-
lyzing the transcriptional profile of A. pleuropneumoniae
serotype 5b during iron restriction grown in BHI-med-
ium [17]. We therefore speculate that the ApxIVA
expression might be due to using customized growth
conditions (iron-restriction in combination with supple-
mented PPLO-medium, see in Methods). Other reports
describing the lack of apxIVA expression in culture
either used BHI-medium [13] or PPLO-medium supple-
mented with horse serum [30] for growth of A.
pleuropneumoniae.
The “detergent-wash” vaccine contains several proteins
encoded by genes only expressed or upregulated in vivo
as identified by IVET [33], SCOTS [34,35] or transcrip-
tional profiling [36]. Proteins relevant for in vivo survival
of A. pleuropneumoniae that were identified by STM
[37,38] are also present in the vaccine. Six of the abun-
dant proteins were shown previously to be induced in
vivo during acute infection (ApxIVA, TbpA, TufB,
OmpA1, OmpA2, and HgbA, [34]). Further, TufB, AasP,
DnaK, GapA and RplC had been identified as expressed
in chronically infected lung by A. pleuropneumoniae
[35]. Furthermore, the proteins OmpP2, ZnuA and
APP7_2020 are considered as being virulence-associated,
since the respective STM mutants were attenuated [38].
A recent study on transcriptional profiling of A. pleur-
opneumoniae during the acute phase of infection
detected four of the proteins identified in the “deter-
gent-wash”, namely TolB, ApxIVA, APP7_0979, and Irp
[36]. APP7_0979 is a conserved lipoprotein [12,39] and
was among the highest in vivo induced proteins [36].
The analyzed subunit vaccine was highly enriched in
immunogenic proteins. A recent immunoproteomic
analysis of secreted and outer membrane proteins from
A. pleuropneumoniae serotype 3 revealed 30 immuno-
genic proteins [13] of which 18 were also identified in
the analyzed subunit vaccine. Six of these proteins
( A p x I I I A ,F r p B ,T u f B ,O m p A 1 ,O m p A 2a n dY f e A )
were among the 14 most abundant proteins; an addi-
tional five proteins among the 14 most abundant pro-
teins were identified as immunogenic elsewhere
including the ApxIA [40] and ApxIVA [30] toxin, as
well as the iron repressible transferring binding pro-
teins TbpA and TbpB [41] and the outer membrane
lipoprotein OmlA [42].
As the immunoproteome of A. pleuropneumoniae has
been extensively studied [13] we set out to identify
cross-reactive antigens. Immunization of pigs with the
presented subunit vaccine comprised of serotypes 1, 2,
and 5 led to formation of antibodies against seven dif-
ferent serotype 7 proteins of which six (TufB, ApxIIA,
D15, FrpB, OmpA1, OpmA2) were already known [13]
except for UshA, which is a periplasmic protein catalyz-
ing the degradation of external UDP-glycose to uridine,
glycose-1-phosphate and inorganic phosphate [43].
Convalescent sera of pigs obtained upon experimental
infection with serotype 7 detected 13 immunogenic pro-
teins of the subunit vaccine of which seven were already
described as immunogenic (TufB, D15, OmpA1,
ApxIIIA, FkpA, ZnuA [13], and ApxIA [40]). The pro-
teins RpsA, Tal, APP7_0756, FusA, YfeA, and UshA are
cross-reactive immunogenic antigens that have not been
described for A. pleuropneumoniae before. YfeA is the
periplasmic binding protein of an ABC transport system
for iron and manganese acquisition and deletion of this
ABC system renders Yersinia pestis avirulent [44]. In the
porcine pathogen Haemophilus parasuis,w h i c hi s
related to A. pleuropneumoniae, YfeA has been recently
identified as an cross-reactive immunogenic protein
[45]. Based on BLAST analysis, APP7_0756 is also the
periplasmic component of an ABC transport system
needed for iron acquisition.
In total, infection with a live A. pleuropneumoniae led
to formation of more cross-reactive antibodies than
immunization using the described subunit vaccine. Thus
several proteins were only detected by convalescent sera
(RpsA, FusA, ApxIA, ApxIIIA, Tal, FkpA, ZnuA, YfeA
and APP7_0756), although they are present in the subu-
nit vaccine. Live bacteria seem to induce an even stron-
ger immune response than the subunit vaccine, which is
in accordance with the findings that pigs surviving nat-
ural or experimental infection are at least partially pro-
tected from clinical symptoms upon infection with
another serotype [46,47].
The analyzed subunit vaccine was comprised of deter-
gent extracted proteins from three different serotypes of
A. pleuropneumoniae in order to increase the number of
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that a serotype specific antigen from one or the other
serotype is cross-reactive against another serotype was
increased. BLAST analysis showed that the identified
immunogenic proteins were highly conserved between
the different A. pleuropneumoniae serotypes explaining
the observed cross-reactivity. Several of the identified
proteins are ideally suited as vaccine components
against A. pleuropneumoniae based on their conserva-
tion [14,26].
The different Apx toxins of A. pleuropneumoniae are
cross-reactive although sharing low homology. Immune
sera of pigs vaccinated with the subunit vaccine,
detected the ApxIIA toxin from serotype 7, although
ApxIIA was not present in the subunit vaccine. On the
other hand convalescent sera of pigs infected with sero-
type 7, which exclusively expresses the apxIIA gene,
detected the ApxIA and ApxIIIA proteins of the vaccine.
The Apx toxins share as a common structural feature a
tandem array of a nine amino acid repeat [48] which
might cause their cross-reactivity.
Conclusions
We characterized the protein components of a non-
recombinant DIVA subunit vaccine against A. pleurop-
neumoniae prepared by “detergent-wash” and we
showed that secreted and outer membrane proteins
were highly enriched with many of these proteins being
proven as immunogenic, transcribed in vivo or required
for survival in the host. The ApxIVA protein was for
the first time identified from in vitro grown A. pleurop-
neumoniae as part of the subunit vaccine. The subunit
vaccine led to formation of cross-reactive antibodies and
contained several antigens that have not been described
as immunogenic before. These results rationalize the
cross-serotype protective efficacy of the “detergent-
wash"-based subunit vaccine observed previously.
Methods
Bacterial strains and growth conditions
A. pleuropneumoniae strains were cultured at 37°C in a
shaking incubator at 180 rpm in PPLO medium (Difco,
Augsburg, Germany) supplemented with NAD (10 μg/
ml; Merck, Darmstadt, Germany), L-cysteine hydro-
chloride (260 μg/ml; Sigma, Deisenhofen, Germany), L-
cystine dihydrochloride (10 μg/ml; Sigma), dextrose (1
mg/ml) and Tween
® 80 (0.1%).
“Detergent-wash” extraction of surface-associated
proteins from iron restricted cultures for application as a
subunit vaccine
For preparation of surface-associated proteins, apxIIA
deletion mutants of A. pleuropneumoniae serotype 1
(ATCC 27088), 2 (DM322/5), 5 (K1711/84) [21] and the
wild type of serotype 7 (AP76, [49]) were incubated in
150 ml of supplemented PPLO medium to an OD600 of
0.2. Then diethylentriamine-pentaacetic acid calcium tri-
sodium salt hydrate (Na3CaDTPA, Fluka Chemika and
BioChemika, Germany, permitted as a drug component
for livestock) was added to a final concentration of 150
μM in order to induce iron restrictive conditions. Bac-
t e r i aw e r ef u r t h e rg r o w nt oa nO D 600 o f0 . 6-0 . 7f o l -
lowed by addition of 10 mM Tris-HCl (pH 8.0), 50 mM
NaCl and 0.05% [w/v] of the mild detergent sodium
deoxycholate (Sigma, permitted as a drug component
for livestock). After incubation for 30 min at 37°C by
shaking at 180 rpm, cultures were centrifuged for 15
min at 8,000 × g to remove cells. The cell-free culture
supernatant (CFS), containing surface-associated pro-
teins, was sterile-filtrated (0.22 μm pore size filter, Milli-
pore, Billerica, USA) and stored at -20°C until further
use [20,21]. Proteins from supernatants were precipi-
tated with trichloracetic acid (TCA; 20% [w/v] final con-
centration) overnight and harvested by centrifugation
(15,000 × g, 30 min). Protein pellets were washed with
acetone and solubilized for 1-D PAGE in 50 mM Tris-
HCl (pH 7.2), 150 mM NaCl or for 2-D PAGE in a buf-
fer containing 30 mM Tris-HCl pH 8.5, 7 M urea [Roth,
Karlsruhe, Germany], 2 M thiourea [Sigma], 4% [wt/vol]
CHAPS [Roth]. Insoluble material was removed by cen-
trifugation at 16,000 × g for 5 min in a benchtop centri-
fuge. Protein concentration was determined using the
Pierce 660 nm Protein Assay (Thermo, Pierce, Rockford,
USA).
“Whole vaccine-proteome approach” by 1-D PAGE UPLC-
coupled Q-TOF MS/MS
40 μg protein of each serotype was loaded on a 10.8%
polyacrylamide gel. After gel electrophoresis each lane
was cut into four slices and subjected to tryptic in-gel
digestion as described below. Each digest was then ana-
lyzed by nanoUPLC-coupled Q-TOF tandem mass spec-
trometry as described below with the following
amendment: As samples were still complex, we analyzed
each digest up to three times. Peptides that have been
fragmented once were excluded from fragmentation in
the following mass spectrometric analyses, in order to
enable fragmentation of low intensity peptides. As the
second or third run generally led to only a few new pep-
tide identifications the sample was considered as com-
prehensively analyzed. This analysis was designated the
“whole vaccine-proteome approach”.
2-D gel electrophoresis and 2-D DIGE
For 2-D DIGE 100 μgp r o t e i no fA. pleuropneumoniae
serotypes 1, 2 and 5 were labeled with Cy2, Cy3 and
Cy5, (GE Healthcare, Freiburg, Germany, according to
the manufacturer’s instructions) respectively, pooled and
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parative gels 300 μg protein of each of the vaccine-spe-
cific serotypes was separated individually and
subsequently stained with Coomassie G-250 [50].
2-D gel electrophoresis, scanning of DIGE gels and
data analysis were performed as described previously
[16]. Briefly, Immobiline
® DryStrips (GE Healthcare) of
24 cm length with a pI gradient from 3 to 11 were used.
Samples were loaded into anodal sample cups and sub-
sequently focused using an Ettan™ IPGphor™ (GE
Healthcare). For second dimension the IPG strips were
placed on the top of 12.5% polyacrylamide gels that had
been precast with low-fluorescent glass plates (GE
Healthcare) using an Ettan™ DALTsix gel caster (GE
Healthcare). The second-dimension SDS-PAGE was car-
ried out using the Ettan™ Daltsix Electrophoresis Sys-
tem (GE Healthcare). Gels with fluorescently labeled
proteins were scanned on a Typhoon Trio™ scanner
(GE Healthcare). Relative spot intensities between the
different serotypes were compared using the DIA tool of
the DeCyder™-Software (GE Healthcare).
In-gel digestion
Spots of interest were excised from preparative gels,
trypsinized and peptides were recovered according to
standard procedures [51]. Briefly, the gel pieces were
dehydrated with acetonitrile (ACN, Merck), rehydrated
with NH4HCO3 buffer (100 mM) containing DTT (10
mM; Roth), and then treated with iodoacetamide (100
mM; Sigma) in NH4HCO3 (100 mM). Dehydration and
rehydration were repeated, and then dehydrated gel
pieces were rehydrated with buffer (50 mM NH4HCO3)
containing trypsin (20 ng/μl, sequencing grade; Pro-
mega, Mannheim, Germany) and incubated for 12 - 16
h at 37°C. Peptides were extracted using NH4HCO3 (50
m M )f o l l o w e db ye x t r a c t i o nb u f f e rc o n t a i n i n gA C N
(50% [vol/vol]; Merck) and formic acid (5% [vol/vol];
Merck). The solution containing the extracted peptides
was evaporated in a vacuum centrifuge.
Protein identification by UPLC-coupled Q-TOF MS/MS or
MALDI-TOF MS
For ESI Q-TOF tandem mass spectrometry peptides
were dissolved in water, and reverse phase chromatogra-
phy using acetonitril as an eluent was performed on a
Waters Aquity nanoUPLC (Milford, USA) device
equipped with an analytical column (Waters,
BEH130C18, 100 μm × 100 mm, 1.7 μm particle size)
c o u p l e do n l i n et oa nE S IQ - T O F( Q - T O FU l t i m a ,
Waters). Peptide spectra were recorded in positive
reflection mode and peptides were automatically sub-
jected to fragmentation (MS/MS). Protein identification
was performed using the program ProteinLynx™ Global
Server (Version 2.1, Waters) by searching against a A.
pleuropneumoniae genome database (actinobacillus
+pleuropneumoniae+taxonomy_715.fasta) downloaded
at http://www.uniprot.org/ from the Protein Knowledge-
base (UniProtKB) on 27.12.2009 containing 6552 entries
(2026 entries of serotype 3 strain JL03, 2004 entries of
serotype 5b strain L20, and 2117 entries of serotype 7
strain AP76). This database contained the complete gen-
omes of the serotypes 3, 5, and 7 that were available at
the date of analysis and was applied for identification of
proteins obtained from serotype 1, 2, 5 and 7.
Alternatively, MALDI-TOF MS was carried out on a
VoyagerDE Pro workstation (Applied Biosystems, USA).
Peptides were dissolved in ACN (50% [vol/vol], Merck),
formic acid (0.1% [vol/vol] Merck), mixed with an equal
volume of matrix (a-cyano-4-hydroxy-cinnamic acid
[Bruker Daltonics, Billerica, USA], 5 mg/ml in 50% acet-
onitrile with 0.1% trifluoroacetic acid) and then spotted
on the target plate. Peptide spectra were acquired in
positive reflection mode, averaging about 1000 laser
shots per MALDI-TOF spectrum. Mass spectra were
calibrated using the calibration mixtures CalMix1 and
CalMix2 (Applied Biosystems). Peptide mass lists were
generated from peptide spectra using the Applied Bio-
systems Data Explorer
® V4 . 8s o f t w a r e .T h ep e p t i d e
mass lists were used to perform the peptide mass finger-
print algorithm on the Mascot web site http://www.
matrixscience.com by searching against the NCBI non-
redundant database or a respective sub-database. Typi-
cally, the search algorithm was set to allow carbamido-
methylation on cysteine residues, oxidation on
methionine residues, and a maximum of 1 missed clea-
vage. The peptide mass tolerance was up to 40 ppm.
Proteins were considered as identified when the prob-
ability-based score was above the significance threshold
(p ≤ 0.05). For some proteins we could not obtain a suf-
ficiently high score. If further criteria were fulfilled we
included these proteins into the list of identifications.
Thus, we compared the calculated molecular mass and
isoelectric point values from the identified proteins with
the observed values on the 2-D gel. Additionally, if a
protein with a non-significant score was part of a hori-
zontal series of spots with adjacent identical proteins we
included this identification.
Quality evaluation of proteomics results
For quality evaluation of proteomics results we deter-
mined the false discovery rate (FDR), applying the
online version of the Decoy Database Buildner soft-
ware tool (http://www.medizinisches-proteom-center.
de, [52]). As a target database we used the A. pleurop-
neumoniae database actinobacillus+pleuropneumoniae
+taxonomy_715.fasta. A decoy database was generated
by reversing the amino acid sequences in the target
database. The spectra were then searched against this
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of different proteins identified from the decoy database
search (false positives, FP) divided by the sum of FP
and the number of different proteins identified from
the target database search (true positives, TP; FDR =
FP/(FP + TP)).
Immunoblotting
CyDye™ (GE Healthcare) labeled proteins were sepa-
rated by 2-D gel electrophoresis and transferred to
nitrocellulose membranes (Protran BA85 0.45 μm,
Schleicher and Schuell, Dassel, Germany) using the
MultiphorTM II system (GE Healthcare). The blotting
membrane was incubated with porcine sera. Convales-
cent sera were obtained from pigs 21 days post experi-
mental infection with A. pleuropneumoniae serotype 7
strain AP76. Immune-sera of pigs vaccinated with the
subunit vaccine were obtained six weeks after initial and
three weeks after booster immunization. Sera were
diluted 1:100 in PBST (8 g NaCl, 0.2 g KH2PO4,1 . 4 4g
Na2HPO4, 0.2 g KCl, 0.5 ml Tween 20, ad 1000 ml). As
second antibody an alkaline phosphatase-conjugated
goat anti swine IgG antibody (Jackson ImmunoResearch
Laboratories, Dianova, Hamburg, Germany) was used in
a 1:5,000 dilution. BCIP (5-bromo-4-chloro-3-indol
phosphate) and NBT (nitro blue tetrazolium) were used
as substrates for visualization of immunogenic proteins.
Immunogenic proteins on Western blots were assigned
to corresponding spots on preparative Coomassie-
stained gels, which were run in parallel with the same
protein preparation, allowing mass spectrometric identi-
fication of the respective proteins.
Additional material
Additional file 1: Figure S1: 1-D PAGE separation of “detergent-
wash” proteins. “Detergent-wash” proteins from serotypes 1, 2 and 5
(subunit vaccine) and from serotype 7 were separated on a
polyacrylamide gel. Each lane was divided into 4 pieces (A-D) and
proteins were in-gel digested with trypsin, extracted from the gel piece
and then analyzed by UPLC-coupled Q-TOF tandem mass spectrometry.
Additional file 2: Table S1: List of all proteins identified in the A.
pleuropneumoniae “detergent wash” preparations upon 1-D PAGE.
Additional file 3: Table S2: List of proteins identified from 2-D gels.
Additional file 4: Figure S2: Preparative 2-D gels of “detergent-
wash” proteins. “Detergent-wash” proteins of serotypes 1, 2, 5 and 7
were separated on individual 2-D gels. Proteins were stained with
colloidal Coomassie blue and proteins of interest were picked from these
gels, trypsinized and analyzed by mass spectrometry. The numbers on
each spot, that has been identified, are consecutive and allow the
finding of the respective spot in Figure 1 and 2.
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